Form D · Venture Capital Fund

Samsara BioCapital, L.P.

Palo Alto, CA · CIK 0001699737

Offering snapshot reported Dec 31, 2020 · SEC filing

Reported sold
Yet to sell
Offering amount: $500M
Investors reported
0
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Yet to occur
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 31, 2020InitialYet to sellNo comparison0SEC filing
Apr 20, 2018Amendment$310,090,000$49,500,000vs Mar 22, 201857SEC filing
Mar 22, 2018Amendment$260,590,000No comparison51SEC filing
Mar 21, 2017InitialYet to sellNo comparison0SEC filing

Offering details

Securities
Equity, Pooled investment fund
Exemptions
06b, 3C, 3C.7
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-385006
The amount above excludes capital commitments made to the Issuer in connection with a distinct Regulation S offering.

Source: Form D, filed Dec 31, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

SAMSARA BIOCAPITAL, L.P.

Investment adviser: SAMSARA BIOCAPITAL, LLC

Gross asset value
$1.9B
Beneficial owners
168
ADV minimum commitment
$50K

Reported in Form ADV on Jun 26, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator HEDGESERV CORPORATION DUBLIN, Ireland Investor statements: Yes (provided to all investors) Related to adviser: No
Auditor KPMG, LLP SAN FRANCISCO, California, United States
Custodian J.P. MORGAN SECURITIES LLC BOSTON, Massachusetts, United States Related to adviser: No
Custodian MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED NEW YORK, New York, United States Related to adviser: No
Prime broker CITIGROUP GLOBAL MARKETS INC. SAN FRANCISCO, California, United States
Prime broker JEFFERIES LLC NEW YORK, New York, United States
Provider details
Annual audit
Yes
Prime brokers
Yes
Custodians
Yes
Administrator other than the adviser
Yes
External marketing
No

KPMG, LLP
PCAOB 185

J.P. MORGAN SECURITIES LLC
SEC 8-35008

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
SEC 8-7221

CITIGROUP GLOBAL MARKETS INC.
CRD 7059 · SEC 8-8177

JEFFERIES LLC
CRD 2347 · SEC 8-15074

Filing source

Form ADV 2115975 · Jun 26, 2026 · Schedule D 7.B.(1), fund 805-8756530482

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Srinivas Akkaraju Director
Michael Dybbs Director
N/A Samsara Biocapital Gp, Llc Director
N/A N/A Samsara Bio Capital Gp, Llc Director

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:
628 Middlefield Road
Palo Alto, CA, 94301